Athena Capital Advisors LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 314 shares of the medical technology company’s stock, valued at approximately $49,000.
Several other institutional investors also recently made changes to their positions in SYK. Oregon Public Employees Retirement Fund grew its holdings in shares of Stryker by 8,029.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,075,473 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 6,000,739 shares during the last quarter. Capital International Investors bought a new stake in Stryker during the 3rd quarter worth approximately $831,822,000. Capital World Investors grew its holdings in Stryker by 987.2% during the 3rd quarter. Capital World Investors now owns 1,657,979 shares of the medical technology company’s stock worth $294,590,000 after acquiring an additional 1,505,479 shares during the last quarter. Winslow Capital Management LLC grew its holdings in Stryker by 215,255.1% during the 3rd quarter. Winslow Capital Management LLC now owns 1,109,079 shares of the medical technology company’s stock worth $197,061,000 after acquiring an additional 1,108,564 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in Stryker by 61.1% during the 3rd quarter. Alliancebernstein L.P. now owns 2,448,502 shares of the medical technology company’s stock worth $435,050,000 after acquiring an additional 928,279 shares during the last quarter. 74.26% of the stock is currently owned by institutional investors.
Shares of NYSE SYK opened at $187.64 on Thursday. The company has a market capitalization of $69.62 billion, a PE ratio of 25.67, a PEG ratio of 2.30 and a beta of 0.86. Stryker Co. has a 52-week low of $144.75 and a 52-week high of $188.09. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.41 and a current ratio of 2.02.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.15 by $0.03. The firm had revenue of $3.80 billion for the quarter, compared to the consensus estimate of $3.73 billion. Stryker had a net margin of 26.12% and a return on equity of 27.60%. On average, equities research analysts expect that Stryker Co. will post 8.12 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.11%. Stryker’s dividend payout ratio (DPR) is currently 28.45%.
In related news, insider Timothy J. Scannell sold 5,282 shares of the business’s stock in a transaction on Wednesday, January 16th. The shares were sold at an average price of $163.50, for a total transaction of $863,607.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Bijoy Sagar sold 2,361 shares of the business’s stock in a transaction on Friday, December 7th. The shares were sold at an average price of $171.24, for a total transaction of $404,297.64. Following the transaction, the vice president now owns 2,361 shares in the company, valued at approximately $404,297.64. The disclosure for this sale can be found here. Insiders sold a total of 47,925 shares of company stock worth $8,384,790 in the last 90 days. Corporate insiders own 7.30% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a report on Monday, February 4th. SunTrust Banks boosted their target price on shares of Stryker to $205.00 and gave the stock a “positive” rating in a report on Monday, February 4th. Credit Suisse Group raised shares of Stryker to an “outperform” rating in a report on Thursday, January 31st. Canaccord Genuity boosted their target price on shares of Stryker from $185.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, January 30th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Stryker in a report on Friday, January 18th. Seven investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $185.37.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: Can systematic risk be avoided?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.